Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 10;9:14499. doi: 10.1038/s41598-019-51090-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

MCL1 and TAZ are potential combinational drug targets for NSCLC treatment. (A) Validation of selected synergistic genes with cell proliferation assay in H1299 cells. The relative fold change between T14 and T0 of each cell line to that of sgCtrl cell line was calculated and presented as mean ± SD (n = 3). “*” represents the differences between cells expressing sgTAZ + sgTarget and those expressing individual sgTAZ or sgTarget were significant with P < 0.05. See also Fig. S3B for validation of non-TAZ interactive genes. (B) Validation of MCL1 and TAZ interaction in H1299 cells with inhibitors. H1299 cells were treated with MCL1 inhibitor S63845 alone or together with Verteporfin to target TAZ at relative concentrations mentioned in the figure for 3 days. Then cell viability was measured through CellTiter-Glo (Promega), the rate of inhibition or viability was further calculated based on the measured values of control (DMSO) and those treated with drugs. (C) A 2D plot of Bliss synergy score was generated with SynergyFinder showing that the two inhibitors used in (B) has synergistic effect. (D) Validation of MCL1 and TAZ interaction in A549 cells with inhibitors. The treatment was similar as described in (B). E. Bliss synergy score of treatment performed in (D).